Feature article / 2 Sep, 2026

Hong Kong OncoCare Cancer Centre and Panboron (Hainan) BNCT Hospital Sign Strategic Partnership Agreement

Hong Kong OncoCare Cancer Centre and Panboron (Hainan) BNCT Hospital Sign Strategic Partnership Agreement

Establishing a Cross-Border Oncology Collaboration Framework and Opening a New Chapter in BNCT Healthcare Cooperation

【Hong Kong · September 2, 2026】OncoCare (Hong Kong) ("OncoCare") and Panboron (Hainan) BNCT Hospital ("Panboron Hospital") have officially signed a strategic partnership agreement. Leveraging the special healthcare policies of the Boao Lecheng International Medical Tourism Pilot Zone, both parties will jointly establish a Cross-Border Oncology Collaboration Framework. The partnership will focus on BNCT (Boron Neutron Capture Therapy) clinical services, international patient referrals, multidisciplinary teleconsultations (MDT), and post-treatment follow-up care, providing professional oncology services to patients across China and the Asia-Pacific region.

Joining Forces: Comprehensive Oncology Resources Brought to Boao Lecheng

OncoCare, a member of Tamarind Health, one of Asia's leading integrated oncology healthcare groups, operates five centres across Central and Tsim Sha Tsui in Hong Kong and serves more than 20,000 patient visits annually.

The organisation provides a full spectrum of cancer services, including radiation therapy, targeted therapy, immunotherapy, and in-clinic chemotherapy. It also offers surgical and nursing services for patients with colorectal diseases, cardiothoracic and lung conditions, breast disease, and respiratory illnesses. In 2025, OncoCare formally joined Tamarind Health, creating strong synergies with the Group's healthcare network across Singapore, Mainland China, Hong Kong, Malaysia, the Philippines, and Vietnam.

Panboron (Hainan) BNCT Hospital, located in the Boao Lecheng International Medical Tourism Pilot Zone, is a subsidiary of Hong Kong-listed China Biotech Services Holdings Limited (8037.HK). The hospital is the first institution in China and the third globally authorised to conduct clinical BNCT treatments. Initially focused on head and neck cancers, its indications are progressively expanding to other solid tumours.

Recognised as a cutting-edge precision oncology technology, BNCT offers significant benefits, including highly targeted treatment and reduced side effects, earning its reputation as the "Fifth Cancer Treatment Modality." Since officially commencing patient care in March this year, the Hospital has completed nearly 50 clinical BNCT treatments. In early August 2026, a team of specialists at the Hospital released real-world three-month follow-up data for the first 10 head and neck cancer patients, showing an objective response rate (ORR) of 80 per cent. These patients were all end-stage head and neck cancer patients with inoperable or advanced recurrent disease; the ORR for traditional chemotherapy or targeted therapy is typically between 10 per cent and 20 per cent.

Collaboration Highlights: Building a Full-Service Model of "Overseas Assessment + Domestic Treatment + Overseas Follow-Up"

Under the agreement, the two parties will establish a bilateral referral mechanism for eligible oncology patients seeking cross-border care. OncoCare will be responsible for patient education and informed communication, preliminary screening and assessment, referral coordination, travel and treatment arrangements, as well as rehabilitation and follow-up care in Hong Kong and overseas. Panboron Hospital will be responsible for BNCT clinical treatment, inpatient management, medical quality and safety, and the timely sharing of treatment progress with OncoCare.

Both institutions will also conduct joint MDT consultations for pre-screened patients to evaluate clinical suitability and develop personalised treatment plans. This framework is designed to ensure that every cross-border patient receives comprehensive multidisciplinary support throughout assessment, treatment, and recovery.

Shawn Liu, Chairman of the China Biotech Services Holdings Limited, stated at the signing ceremony that the collaboration between the two parties centres on four key areas: a fast-track channel for international medical consultation and treatment, the regularisation of international multidisciplinary team (MDT) consultations, joint scientific research and real-world studies, and talent development and academic exchange. “The agreement signed today represents not only a pledge of trust, but also a commitment to responsibility.”

Mr. Lim Eng Seng, Group CEO of Tamarind Health, the parent company of OncoCare, said: " This partnership is an important step for OncoCare in continuously promoting cross-border medical collaboration and expanding advanced treatment options. We look forward to enabling patients in need to more conveniently access cutting-edge treatment options, including BNCT, and to receiving more comprehensive and continuous medical support throughout the diagnosis, treatment, and rehabilitation process, striving to achieve better treatment outcomes and quality of life."

Strategic Importance: Policy Advantages Combined with International Healthcare Expertise

This partnership carries significant strategic value.

First, it fully leverages the preferential healthcare policies of the Boao Lecheng Pilot Zone, integrating internationally advanced BNCT technology with oncology expertise from Hong Kong and Singapore to create a complete care pathway encompassing overseas assessment, domestic treatment, and overseas follow-up.

Second, the involvement of Tamarind Health and OncoCare enhances Panboron Hospital's oncology profile and professional influence across China and the broader Asia-Pacific region.

Third, the partnership establishes a two-way patient referral channel, bringing international patients to Hainan for BNCT treatment while also facilitating access for mainland Chinese patients to Hong Kong and Singapore for rehabilitation and other specialist treatments.

Creating Shared Value: International-Quality Oncology Care Without Leaving China

For patients, the partnership provides access to international MDT consultations and advanced BNCT treatment in Hainan without the need for long-distance overseas travel, while ensuring structured follow-up care outside Mainland China.

For Panboron Hospital, OncoCare's international reputation and professional expertise will strengthen referral pathways, increase patient access, enhance confidence in BNCT treatment, improve clinical quality, and support sustainable growth.

For the Boao Lecheng Pilot Zone, the collaboration further strengthens its position as an international oncology treatment destination, supporting the growth of medical tourism, cross-border insurance, and related healthcare services.

Looking Ahead: Expanding the Boundaries of Cross-Border Healthcare Collaboration

Both parties emphasised that this framework agreement marks only the beginning of their collaboration. Future cooperation will include physician practice arrangements, joint clinical protocols, and research partnerships.

As cross-border healthcare collaboration continues to evolve, more innovative cancer treatment technologies and service models are expected to benefit patients across China and the Asia-Pacific region, while contributing to the Healthy China initiative and the high-quality development of the Boao Lecheng Pilot Zone.

 

About OncoCare (Hong Kong)

OncoCare is part of a growing network of clinics across Hong Kong, Singapore, Malaysia, and the Philippines. Founded in 2018, OncoCare Hong Kong joined Tamarind Health, an Asia’s leading integrated oncology-focused group, in 2025.

OncoCare Hong Kong provides expert, integrated cancer care through OncoCare Cancer Centre, as well as diagnostics and surgery for colorectal conditions, cardiothoracic diseases, breast disorders and respiratory conditions through Tamarind Specialists Centre. Together, these services create a clear and seamless care pathway from screening and diagnostic through multidisciplinary treatment —delivering personalised, compassionate care in the heart of the city.

 

About Panboron (Hainan) BNCT Hospital

Panboron (Hainan) BNCT Hospital is located in the Boao Lecheng International Medical Tourism Pilot Zone and is authorized to provide BNCT clinical services. The hospital is dedicated to delivering world-class precision treatment for patients with head and neck cancers and other solid tumours.

Panboron (Hainan) BNCT Hospital is China’s first and currently only approved high-end specialist oncology institution offering boron neutron capture therapy (BNCT). Leveraging the ‘pilot and innovation’ policies of Boao Lecheng in Hainan, the hospital has introduced the globally exclusive NeuCure® BNCT system and Steboronine® boron drug, enabling ‘cell-level’ precision cancer treatment.

The hospital is situated in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China, adjacent to the Wanquan River. With a floor area of 14,011 square metres, it has 40 beds and an annual treatment capacity exceeding 1,500 cases. It is 8 kilometres from Boao Airport and 6 kilometres from the high-speed rail station, offering excellent transport links. Professor Ono Koji, a leading scholar in BNCT, and Professor Wang Junjie, a Chinese expert in brachytherapy, serve as Honorary Presidents, whilst Professor Wang Enmin, a specialist in radiation neurosurgery, serves as President and leads the medical team, focusing on precision radiotherapy for unresectable locally advanced and cervical head and neck cancers.

The hospital commenceas operations and begin receiving patients in March 2026. It is a subsidiary of China Biotech Services (8037.HK), a Hong Kong-listed company, and is committed to establishing a new centre of excellence for precision cancer treatment in China and restoring life for patients with comple

Search